Drug intelligence / Profile preview

TEV-45478

Development stage: Discontinued
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

TEV-45478 is an oral small molecule drug that was developed by Teva Pharmaceutical Industries for the treatment of nonalcoholic steatohepatitis (NASH) in patients who also have type 2 diabetes mellitus. The drug reached Phase 2 clinical trials, but development was discontinued and it is no longer being pursued. Its primary therapeutic areas were digestive system disorders and endocrinology/metabolic diseases. The specific molecular target and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on TEV-45478.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-45478.

Explore the full profile